StratifyProstate is a national initiative to provide no-cost tumor sequencing and new clinical trial options to 10,000 men with metastatic prostate cancer, with the goal of broadening access and accelerating drug approvals. StratifyProstate was conceived by leading physicians and researchers from the UCSF Helen Diller Family Comprehensive Cancer Center and Strata Oncology, a precision oncology company located in Ann Arbor, Michigan. Tumor sequencing is provided at no-cost through patient participation in an observational study sponsored by Strata Oncology, called the Strata TrialTM. The study is conducted virtually, and no patient interaction is required with study staff. In some cases, the study team may contact the physician to document treatment selection.